Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 1
Submit an article Journal homepage
425
Views
40
CrossRef citations to date
0
Altmetric
Review

New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder

Kennerly S Patrick Medical University of South Carolina, Department of Pharmaceutical Sciences, 280Calhoun St., QF221A, Charleston, SC29425-0742, USA. [email protected]
,
Mario A González P’Kinetics International, Inc., Pembroke Pines, Florida, USA
,
Arthur B Straughn University of Tennessee Health Science Center, Department of Pharmaceutical Sciences, DrugResearch Laboratory, Memphis, Tennessee, USA
&
John S Markowitz Medical University of South Carolina, Department of Pharmaceutical Sciences, 280Calhoun St., QF221A, Charleston, SC29425-0742, USA. [email protected]
Pages 121-143 | Published online: 22 Apr 2005

Bibliography

  • SWANSON JM, SEARGENT JA, TAYLOR E, SONUGA-BARKE EJS, JENSEN PS, CANT WELL DP: Attention deficit disorder and hyperkinetic disorder. Lancet (1998) 351: 429–433.
  • DULCAN M: The Work Group on Quality Issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psychiatry (1997) 36:85S–121S.
  • HOMER CJ, BALTZ RD, HICKSON GB et al.: Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics (2000) 105:1158–1170.
  • ELIA J, AMBROSINI PJ, RAPOPORT JL: Treatment of attention-deficit-hyperactivity disorder. N EngL J. Med. (1999) 340:780–788.
  • GOLDMAN LS, GENEL M, BEZMAN RJ et al.: Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. J. Am. Med. Assoc. (1998) 279:1100–1107.
  • ROBISON LM, SKAER TL, SCLAR DA, GALIN RS: Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs (2002) 16:129–137.
  • The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (1999) 56:1073–1086.
  • MANNUZZA S, KLEIN RG, BESSLER A, MALLOY P, LAPADULA M: Adult psychiatric status of hyperactive boys grown up. Am. J. Psychiatry (1998) 155:493–498.
  • American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington DC, USA (2000) 85–103.
  • TANNOCK R: Attention deficit hyperactivity disorder: Advances in cognitive, neurobiological, and genetic research. J. Child. PsychoL Psychiatry (1998) 39:65–99.
  • SPENCER T, BIEDERMAN J, WILENS T: Attention-deficit/hyperactivity disorder and comorbidity. Pediatr. Clin. North Am. (1999) 46:915–927.
  • DISCALA C, LESCOHIER I, BARTHEL M, LI G: Injuries to children with attention deficit hyperactivity disorder. Pediatrics (1998) 102:1415–1421.
  • MILBERGER S, BIEDERMAN J, FARONE SV, CHEN L, JONES J: ADHD is associated with early initiation of cigarette smoking in children and adolescents./ Am. Acad. Child. Adolesc. Psychiatry (1997) 36:37–44.
  • BIEDERMAN J, WILENS T, MICK E, SPENCER T, FARAONE SV: Pharmacotherapy of attention deficit/ hyperactivity disorder reduces risk for substance use disorder. Pediatrics (1999) 104:e20–e24.
  • WILENS TE, FARAONE SV, BIEDERMAN J, GUNAWARDENE S: Does stimulant therapy of attention-deficit/ hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics (2003) 111:179–185.
  • MILBERGER S, BIEDERMAN J, FARAONE S et al.: Pregnancy, delivery and infancy complications and attention deficit hyperactivity disorder: issues of gene-environment interaction. Biol. Psychiatry (1997) 41:65–75.
  • NEEDLEMAN HL, GUNNOE C, LEVITON A et al.: Deficits in psychologic and classroom performance of children with elevated dentine lead levels. N EngL J. Med. (1979) 300:689–695.
  • GALILI-WEISSTUB E, SEGMAN RH: Attention deficit and hyperactivity disorder: review of genetic association studies. Isr. J. Psych. Relat. Sci. (2003 40(1):57–66.
  • FARAONE SV, DOYLE AE, MICK E et al.: Meta-analysis of the association between the dopamine D4 gene 7-repeated allele and attention-deficit/hyperactivity disorder. Am. J. Psychiatry (2001) 158:1052–1057.
  • BARR CL, WIGG KG, FENG Y et al: Attention-deficit hyperactivity disorder and the gene for the dopamine D5 receptor. Mol. Psychiatry (2000) 5:548–551.
  • ROHDE LA, ROMAN T, HUTZ MH: Attention-deficit/hyperactivity disorder: current aspects on pharmacogenetics. Pharmacogenomics J. (2003) 3:11–13.
  • LOO SK, SPECTER E, SMOLEN A et al.: Functional effects of the DAT1 polymorphism on EEG measures in ADHD. J. Am. Acad. Child Adolesc. Psych. (2003) 42(8):986–993.
  • KIRLEY A, HAWI Z, PHIL M et al.: Dopaminergic system genes in ADHD: Toward a biological hypothesis. Neuropsychopharmaco/ogy (2002) 27:607–619.
  • WINSBERG BG, COMINGS DE: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am Acad. Child Adolesc. Psychiatry (1999) 38:1474–1477.
  • WIGG K, ZAI G, SCHACHAR R et al.: Attention deficit hyperactivity disorder and the gene for dopamine beta-hydroxylase. Am. J. Psychiatry (2002) 159:1046–1048.
  • MILL J, CURRAN S, KENT L et al.: Association study of a SNAP-25 microsatellite and attention deficit hyperactivity disorder. Am. J. Med. Genet. (2002) 114:269–271.
  • VOLKOW ND, WANG GJ, FOWLER JS et al.: Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry (1998) 155:1325–1331.
  • VOLKOW ND, WANG G-J, FOWLER JS et al.: Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse (2002) 48:181–187.
  • VLES JS, FERON FJ, HENDRIKSEN JG et al.: Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics (2003) 34:77–80.
  • VOLKOW ND, FOWLER JS, WANG G et al.: Mechanism of action of methylphenidate: insights from PET imaging studies./ Attn. Disord. (2002) 6(S.1):31–43.
  • NEWCORN JH, SCHULZ K, HARRISON M et al.: a2-Adrenergic agonists: neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr. Clin. North Am. (1998) 45:1099–1122.
  • SILVER LB: Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children. Pediatr. Clin. North Am. (1999) 46:965–975.
  • BIEDERMAN J, SPENCER T, WILENS T: Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int. Neuropsychopharmacology (2004) 7:77–97.
  • ARNOLD LE, ELLIOTT M, SACHS L: Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J. Conslt. Clin. Psychology (2003) 71(4):713–727.
  • ARNOLD LE: Methylphenidate versus amphetamine: comparative review. J. Attent. Disord. (2000) 3:200–211.
  • FARAONE SV, BIEDERMAN J, ROE C: Comparative efficacy of Adderall and methylphenidate in attention deficit/ hyperactivity disorder: a meta-analysis. J. Clin. Psychopharmacol. (2002) 22:468–473.
  • ZABIK JE, LEVIN RM, MAICKEL RP:Drug interaction with brain biogenic amines and the effects of amphetamine isomers on locomotor activity. PharmacoL Biochem. Behav. (1978) 8:429–435.
  • ARNOLD LE, HUESTIS RD, SMELTZER DJ et al.: Levamphetamine versus dextroamphetamine in minimal brain dysfunction. Arch. Gen. Psychiatry (1976) 33:292–301.
  • GREENHILL LL, HALPERIN JM, ABIKOFF H: Stimulant medications. J. Am. Acad. Child. Adolesc. Psychiatry (1999) 38:503–512.
  • FARAONE SV, SHORT EJ, BIEDERMAN J, FINDLING RL, ROE C, MANOS MJ: Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int. J. NeuropsychopharmacoL (2002) 5:121–129.
  • PELHAM WE, ARONOFF HR, MIDLAM JK et al.: A comparison of Ritalin and Adderall: Efficacy and time-course in children with attention-deficit/ hyperactivity disorder. Pediatrics (1999) 103:E43.
  • MARKOWITZ JS, STRAUGHN AB, PATRICK KS: Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy (2003) 23(10):1282–1299.
  • ANDRIOLA MR: Efficacy and safety of methylphenidate and pemoline in children with attention deficit hyperactivity disorder. Curr. Ther. Res. Clin. Exp. (2000) 61:208–215.
  • KRATOCHVIL CJ, HEILIGENSTEIN JH, DITTMANN R et al.: Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Am. Acad. Child. Adolesc. Psychiatry (2002) 41:776–784.
  • HEIL SH, HOLES HW, BICKEL WK et al.: Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug abusers. DrugAlcohol Depend. (2002) 67:149–156.
  • GLASE SA, ROBERTSON DW, WISE LD: Attention deficit disorder: patholophysiology and design of new treatments. Ann. Rep. Med. Chem. (2002) 37:11–20.
  • PATRICK KS, CALDWELL RW, FERRIS RM et al.: Pharmacology of the enantiomers of threo-methylphenidate. J. PharmacoL Exp. Ther. (1987) B:152–158.
  • VOLKOW ND, WANG G-J, FOWLER JS et al.: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transpoters in the human brain. Lift Sci. (1999) 65:7–12.
  • RUSKIN DN, BERSTROM DA, SHENKER A, FREEMAN LE, BACK D, WALTERS JR: Drugs used in the treatment of attention-deficit/hyperactive disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action. Biol. Psychiatry (2001) 49:340–350.
  • VOLKOW ND, WANG G-J, FOWLER JS et al.: Nonhedonic' food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse (2002) 44:175–180.
  • SOLANTO MV: Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res. 1998 94:127–152.
  • SEEMAN P, MADRAS B: Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav. Brain Res. (2002) 130:79–83.
  • PATRICK KS, MARKOWITZ JS: Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder: a review. Hum. PsychopharmacoL (1997) 12:527–546.
  • SCHENK JO: The functioning neuronaltransporter for dopamine: kinetic mechanisms and effects of amphetamine, cocaine and methylphenidate. Prog. Drug Res. (2002): 59:111–131.
  • SEEMAN P, MADRAS BK: Anti-hyperactivity medication: methylphenidate and amphetamine. Mol. Psychiatry (1998) 3:386–396
  • HITRI A, HURD YI,, WYATT RJ et al.: Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. J. Clin. NeuropharmacoL (1994) 17:1–22.
  • HERON C, COSTENTIN J, BONNET J-J: Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur. PharmacoL (1994) 264:391–398.
  • WIDDOP A (Ed.), 3rd edition, Clarke's Analysis of Drugs and Poisons (Volume 2). Pharmaceutical Press, London (2004):1260–1262.
  • •The pharmaceutical and metabolic chemistry of MPH.
  • SIEGAL S, LACHMAN L, MALSPEIS L: A kintic study of the hydrolysis of methyl Di.-phenyl-2-piperidylacetate. J. Pharmaceut. Sci. (1959) 48:431–439.
  • FARAJ BA, ISRAILI ZH, PEREL JM et al.: Metabolism and disposition of methylphenidate-14C: Studies in man and animals. J. PharmacoL Exp. Ther. (1974) 191:535–547.
  • CHAN Y-PM, SOLDIN SJ, SWANSON JMI.: Gas chromatographic/mass spectrometric analysis of methylphenidate (Ritalin) in serum. Clin. Biochem. (1980) 13:266–272.
  • MEYER MC, STRAUGHN AB, JARVI EJ et al.: Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability. Pharm. Res. (2000) 17:381–384.
  • SHADER RI, HARMATZ JS, OSTERHELD JR, PARMALEE DX, SALLEE FR, GREENBLATT DJ: Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. J. Clin. PharmacoL (1999) 39:775–785.
  • MIDHA KK, MCKAY G, RAWSON MJ, KORCHINSKI ED, HUBBARD JW: Effects of food on the pharmacokinetics of methylphenidate. Pharmaceut. Res. (2001) 18:1185–1189.
  • MODI NB, WANG B, HU WT, GUPTA SK: Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HC1 in healthy subjects. Biopharm. Drug Dispos. (2000) 21:23–31.
  • PENTIKIS HS, SIMMONS RD, BENEDICT MF, HATCH SJ: Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered on food or as an intact capsule. J. Am Acad. Child. Adolesc. Psychiatry (2002) 41:443–449.
  • LEE L, KEPPLE J, WANG Y et al.: Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharmaceut. Drug Dispos. (2003) 24:233–243.
  • HUNGUND BL, PEREL JM, HURWIC MJ, SVERD J, WINSBERG BG. Pharmacokinetics of methylphenidate in hyperkinetic children. Br. J. Clin. PharmacoL (1979) 8:571–576.
  • PATRICK, KS, ELLINGTON KR, BREESE GR: Distribution of methylphenidate and p-hydroxymethylphenidate in Rat. J. PharmacoL Exp. Ther. (1984) 231:61–65.
  • MODI NB, LINDEMULDER G, GUPTA SK: Single-and multiple-dose pharmacokinetics of oral once-a-day osmotic controlled-release OROS1'm (methylphenidate HC1) formulation. J. Clin. PharmacoL (2000) 40:379–388.
  • MODI NB, WANG B, NOVECK RJ et al.: Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic controlled-release oral delivery system. J. Clin. PharmacoL (2000) 40:1141–1149.
  • ROCHDI M, GONZALEZ MA, HIRSHEY DIRKSEN SJ: Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Int. J. Clin. PharmacoL Ther. (2004) 42(5):285–292.
  • AOYAMA T, KOTAKI H, SASAKI T et al.: Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Eur. J. Clin. PharmacoL (1993) 44:79–84.
  • SRINIVAS NR, HUBBARD JW, KORCHINSKI ED et al.: Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm. Res. (1993) 10:14–21.
  • CHAN Y-P, SWANSON JM, SOLDIN SS et al.: Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics (1983) 72:56–59.
  • SHAYWITZ SE, HUNT RD, JATLOW P et al.: Psycholopharmacology of attention deficit disorder: Pharmacokinetic, neuroendocrine, and behavioral measures following acute chronic treatment with methylphenidate. Pediatrics (1982) 69:688–694.
  • WARGIN W, PATRICK K, KILTS C et al.:Pharmacokinetics of methylphenidate in man, rat and monkey. J. PharmacoL Exp. Ther. (1983) 226:382–386.
  • BIRMAHER B, GREENHILL LL, COOPER TB, FRIED J, MAMINSKI B: Sustained release methylphenidate: Pharmacokinetic studies in ADDH males. J. Am. Acad. Child Adolesc. Psychiatry (1989) 28:768–772.
  • PATRICK KS, STRAUGHN AB, JARVI EJ, BREESE GR, MEYER MC: The absorption of sustained- release methylphenidate formulation compared to an immediate-release formulation. Biopharm. Drug Dispos. (1989) 10:165–171.
  • LIES HJ, FAULER G, RASOTNIG G, WINDISCHHOFER: Negative ion chemical ionization for the determination of methylphenidate in human plasma by stable isotope dilution gas chromatography/mass spectrometry. J. Mass Spectrom. (2000) 35:1100–1104.
  • MARKOWITZ JS, DEVANE CL, BOULTON DW et al.: Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and alcohol. Drug Metab. Dispos. (2000) 25:620–624.
  • GONZALEZ MA, PENTIKIS HS, ANDERI N et al.: Methylphenidate bioavailability from two extended-release formulations. Int. J. Clin. PharmacoL Ther. (2002) 40:175–184.
  • MARKOWITZ JS, STRAUGHN AB, PATRICK KS et al.: Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin. Pharmacokinet. (2003) 42:393–401.
  • WIGAL SB, SANCHEZ DY, DECORY HH, D'IMPERIO JM, SWANSON JM: Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. j Appl. Res. (2003) 3:46–63.
  • LIM HK, HUBBARD J, MIDHA KK: Development of enantioselective gas chromatographic quantitation assay for dl-threo-methylphenidate in biological fluids. J. Chromatogr. (1986) 378: 109–123.
  • SRINIVAS NR, QUINN D, HUBBARD JW MIDHA KK: Stereoselective disposition of methylphenidate in children with attention-deficit disorder. J. PharmacoL Exp. Ther. (1987) 241:300–306.
  • HUBBARD JW, SRINIVAS NR, QUINN D, MIDHA KK: Enantioselective aspects of the disposition of all dl-threo-methylphenidate after the administration of a sustained-release formulation to with attention deficit-hyperactivity disorder. J. Pharma. Sci. (1989) 78:944–947.
  • AOYAMA T, KOTATAKI H, HONDA Y, NAKAGAWA F: Kinetic analysis of anantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method. J Pharm. Sci. (1990) 79: 465–469.
  • SRINIVAS NR, HUBBARD JW, MIDHA KK: Enantioselective gas chromatographic assay with electron-capture detection of DL-ritalinic acid in plasma. J. Chromatogr. (1990) 530:327–336.
  • SRINIVAS NR, HUBBARD JW, QUINN D et al.: Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin. PharmacoL Ther. (1992) 52:561–568.
  • SRINIVAS NR, HUBBARD JW, KORCHINISKI ED et al.: Enantioselective pharmacokinetics of DL-threo-methylphenidate in humans. Pharm. Res. (1993) 286:880–881.
  • AOYAMA T, SASAKI T, KOTAKI J: Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. Clin. PharmacoL Ther. (1994) 55:270–276.
  • WONG NY, KING SP, LAUGHTON WB et al.: Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J. Clin. PharmacoL (1998) 38:276–282.
  • RAMOS L, BAKHTIAR K, MAJUMDAR T et al.: Liquid chromatography/ atmospheric pressure chemical ionization tandem mass spectrometry enantiomeric separtation of dl-threo-methylphenidate, (Ritalin7) using a macrocyclic antibiotic as the chiral selector. Rapid Commun. Mass Spectrom. (1999) 13:2054–2062.
  • TEO SK, SCHEFFLER MR, WU A et al.:A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HC1 with and without food. J. an. Pharmacol (2004) 44:173–178.
  • DUCHIN K, CAMPBELL D, LINAREU E: Pharmacokinetics of multiple doses of methylphenidate transdermal system in children with attention deficit hyperactivity disorder. 48th Annual Meeting of the American Academy of Child and Adolescent. Psychiatry (2001).
  • JONKMAN LM, VERBATEN MN, DEBOER D et al.: Differences in plasma concentrations of the d- and l-threo methylphenidate enantiomers in responding and non-responding children with attention-deficit hyperactivity disorder. Psychiatry Res. (1998) 78:115–118.
  • SWANSON JM, VOLKOW ND: Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav. Brain Res. (2002) 130:73–78.
  • SRINIVAS NR, HUBBARD JW, McKAY, HAWES EM, MIDHA KK: In vitro hydrolysis of RR, SS-threo-methylphenidate by blood esterases-differential and enantioselective interspeces differences. Chirality (1991) 3:99–103.
  • DING Y-S, FOWLER JS, VOLKOW ND: Is the l-threo enantiomer of
  • DING YS, GATLEY SJ, THANOS PK et al.: Brain kinetics of methylphenidate
  • PATRICK KS, CALDWELL RW, DAVIS KR, MUELLER RA, BREESE GR: Resolution, metabolism and pharmacology of methylphenidate enantiomers. Fed. Proc. (1986) 46:933.
  • SRINIVAS NR: Role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus?J. Clin. Pharmacol. 2004):115–119.
  • MISTRY B, LESLIE JL, EDDINGTON ND: Influence of input rate on the sterospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations. Chirality (2002) 14:297–304.
  • BAKHIAR R, TSE FLS: Toxicokinetic assessment of methylphenidate (Ritalin®) in a 13-week oral (gavage) toxicity study in rats assay. Rapid Commun. Mass Spectrom. (2003) 17:2160–2162.
  • BUGGE CJ, GRUN I, LJUNGQVIST A et al.: Enantioselective determination of d-and 1-threo-methylphenidate in the pg/ml range in human plasma by LC-MS-MS - abstract. Presented (Podium Session) at the American Association of Pharmaceutical Scientists Annual Meeting (1996).
  • PATRICK KS, KILTS CD, BREESE GR: Synthesis of deuterium labeled methylphenidate, p-hydroxymethylphenidate, ritalinic acid and p-hydroxyritalinic acid./ Label. Compounds Radiopharm. (1981) 9:485–490.
  • SWANSON JM, LERNER M, WIGAL T et al.: The use of laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J. Attent. Disord. (2002) 6:S73–S88.
  • PATRICK KS, KILTS CD, BREESE GR: Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J. Med. Chem. (1981) 29:1237–1240.
  • BARLETT MF, EGGER HP: Disposition an metabolism of methylphenidate in dog and man. Fed. Proc. (1972) 31:537.
  • REDALIEU E, BARTLETT MF, WALDES LM et al.: A study of methylphenidate in man with respect to its major metabolite. Drug Metab. Dispos. (1982) 10:708–709.
  • SUN Z, MURRY DJ, SANGHANI SP et al.: Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1AL Pharmacol Exper. Ther. (2004) 310: 469–476.
  • AOYAMA T, KOTAKI H, IGA T: Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. J. Pharmacobio-Dyn. (1990) 13:647–652.
  • AOYAMA T, KOTAKI H, IGA T: Effect of dose on first pass effect of methylphenidate enantiomers in rats. Xenobio-Metab. Dispos. (1990) 5:527.
  • HERNANDEZ DE, ADCOCK JW, ORLANDO, RC, PATRICK KS, NEMEROFF CB, PRANGE AJ: Prevention of stress gastric ulcers by dopamine agonists in the rat. Lift Sci. (1984) 35(24):2453–2458.
  • PATRICK KS, ELLINGTON KR, BREESE GR et al.: Gas chromatographic-mass spectrometric analysis of methylphenidate andp-hydroxy-methylphenidate using deuterated internal standards. j Chromatogr. B. Biomed. Appl (1985) 343:329–338.
  • BIEDERMAN J, WILENS T, MICK E, MILBERGER S, SPENCER TJ, FARAONE SV: Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. Am. J. Psychiatry (1995) 152:1652–1658.
  • BIEDERMAN J, MICK E, FARAONE SV et al.: Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am. J. Psychiatry (2002) 159:36–42.
  • LAMBERT NM, HARTSOUGH CS: Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J. Learn. Disabil (1998) 31(6):533–544.
  • SCHUBINER H, TZELEPIS A, MILBERGER S et al.: Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. Clin. Psychiatry (2000) 61(4):244–251.
  • MARKOWITZ JS, LOGAN BK, DIAMOND F et al.: Detection of the novel metabolite ethylphenidate following methylphenidate overdose with alcohol co-ingestion. J. Clin. Psychopharmacol (1999) 19:362–366.
  • THOMSON MR, DOWD JJ, MARKOWITZ JS, DEVANE CL, PATRICK KS: Enantioselective transesterification of methylphenidate to ethylphenidate after coadministration with ethanol labstrl. j Clin. Pharmacol (2002) 42:1069.
  • PATRICK KS, WILLIARD RL, MARKOWITZ JS et al.: Synthesis, pharmacology and human formation of ethylphenidate: the transesterification product of methylphenidate and ethanol, Southeastern Reg. Meeting ofAmerican Chem. Society. (Nov 10–13, 2004).
  • JATLOW P, ELS WORTH JD, BRADBERRY CW et al.: Cocaethylene: a neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. Lift Sci. (1991) 48:1787–1794.
  • BOYER CS, PETERSON DR: Enzymatic basis for the transesterification of cocaine in the presence of ethanol: evidence for the participation of microsomal carboxylesterases. J. Pharmacol Exp. Ther. (1992) 260:939–946.
  • BOURLAND JA, MARTIN DK, MAYERSOHN M: Carboxylesterase transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2F16] ethanol: preliminary in vitro findings using a rat liver preparation. J. Pharm. Sci. (1997) 86:1494–1496.
  • PORTOGHESE PS, MALSPEIS L: Relative hydrolytic rates of certain alkyl (b) DL-(2-piperidy1)-phenylacetates. j Pharm. Sci. (1961) 50(6) :494–501.
  • SCHWERI MM, SKOLNICK P, RAFFERTY MF, RICE KC, JANOWSKY AJ, PAUL SM: [°H] Threo-(±)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. Neurochem. (1985) 45:1062–1070.
  • LEVINE BL, CAPLAN YH, KAUFFMAN G: Fatality resulting from methylphenidate overdose. J. Analyt. ToxicoL (1986) 10:209–210.
  • SHORE PA, BRODIE BB, HOGBEN CAM: The gastric secretion of drugs: a pH partion hypothesis. J. Exper. PharmacoL Ther. (1957) 119:361–369.
  • STOECKEL H, HENGSTMANN H, SCHUTTLER J: Pharmacokinetics of fentanyl as a possible explanation for recurrence of respiratory depression. Br. J. Anaesth. (1979) 51:741–745.
  • RITSCHEL WA, ADOLPH S, DENSON DD. Ion-trapping of meperidine: influence of antacid treatments on serum and gartic fluid concentrations. Meth. Find. Exp. Clin. PharmacoL (1990) 12:47–51.
  • Data on file. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2003.
  • KEATING GM, FIGGITT DR Dexmethylphenidate. Drugs (2002) 62:1899–1904.
  • TEO SK, STIRLING DI, THOMAS SD, KHETANI VD: Neurobehavioral effects of racemic threo-methylphenidate and its d and lenantiomers in rats. PharmacoL Biochem. Behav. (2003) 74:747–754.
  • COHEN MR: Extended release drugs. Timing is everything. Nursing (2002) 32(3):18.
  • Medication therapy. In: Barkley RA, editor. Attention Deficit Hyperactivity Disorder-A Handbook for Diagnosis and Treatment, New York: The Guilford Press (1990):573–612.
  • STOWE CD, GARDNER SF, GIST CC, SCHULZ EG, WELLS TG: 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Pediatrics (2002) 36:1142–1149.
  • FINDLING RL, SHORT E, MANOS MJ: Short-term cardiovascular effects of methylphenidate and Adderall. J. Am. Acad. Child. Adolesc. Psychiatry (2001) 40:525–529.
  • ECKERMAN DA, MOY SS, PERKINS AN et al.: Enantioselective behavioral effects of threo methylphenidate in rats. PharmacoL Biochem. Behav. 40:875–880.
  • EFRON D, JARMAN F, BARKER M: Side effects of methylphenidate and dexamphetamine in children with attention deficit disorder: a double-blind, crossover trial. Pediatrics (1997) 100:662–666.
  • NOVARTIS PHARMACEUTICALS CORPORATION. Focalin (dexmethylphenidate HCB package insert. (2001) East Hanover, NJ.
  • SCHEFFLER MR, TEO S, STIRLING D, THOMAS S, KHETANI AV: Multiple dosing of dexmethylphenidate HCL (d-MPH) does not result in accumulation or interconversion to 1-methylphenidate HCL in male and female children labstrl. Clin. PharmacoL Ther. (2003) PII–27.
  • SPENCER T, KIM S, JIANG H et al.: Efficacy of dexmethylphenidate extended-release capsules in adults with attention-deficit hyperactivity disorder. American Psychiatry Association Meeting (2004).
  • SRINIVAS NR, BARBHAIYA RH, MIDI-IA KK: Enantiomeric drug development: issues, considerations, and regulatory requirements. J. Pharm. (2001) 90 (9):1205–1215.
  • M.A.Liebert Publishers, Larchmont, NY 2nd ed). (2000):369–374.
  • ROUHI AM: Chirality at work. Chem. Eng. News (2003) 56–61.
  • SINGH P, BONIELLO S, LIU P et al.: Transdermal iontophoretic delivery of methylphenidate HC1 in vitro. Int. J. Pharmaceut. (1999) 178:121–128.
  • SANE N, McGOUGH JJ: MethyPatch Noven. Curr. Opin. Invest. Drugs (2002) 3(8):1222–1224.
  • AHMED S, IMAI T, YOSHIGAE Y, OTAGIRI M: Stereospecific activity and nature of metabolizing esterases for propranolol in hairless mouse skin, liver and plasma. Life Sci. (1997) 61:1879–1887.
  • TEO SK, STIRLING DI, THOMAS SD, HOBERMAN AM, CHRISTIAN MS, KHETANI VD: The perinatal and neonatal toxicity of d-methylphenidate and dl-methylphenidate in rats. Reprod. Tox. (2002) 16:353–366.
  • TEO SK, SAN RH, WAGNER VO, GUDI R, STIRLING DI, THOMAS SD et al.: Methylphenidate is non-genotoxic in vitro and in vivo assays. Mutat. Res. (2003) 537:67–79.
  • TEO SK, STIRLING DI, HOBERMAN AM et al.: d-methylphenidate and dl-Methylphenidate are not developmental toxicants in rats and rabbits. Bir. Def Res. (Part B) (2003) 68:162–171.
  • DAVIDS E, ZHANG K, TARAZI Fl, BALDESSARINI RJ: Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (2002) 160:92–98.
  • GREENHILL LL, PLISZKA S, DULCAN MK, and the Work Group on Quality Issues: AACAP. Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults./ Am. Acad. Child. Adolesc. Psychiatry (2002) 41(2 Suppl.):265–495.
  • WOLRAICH ML, DOFFING Mk Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs (2004) 18(4):243–250.
  • GREENHILL LL: Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr. Clin. North Am. (1992) 15:1–27.
  • DULCAN MK: Using psychostimulants to treat behavioral disorders of children and adolescents. J. Child AdoL PsychopharmcoL (1990) 1:7–20.
  • PELHAM WE, STURGES J, HOZA J et al.: Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics (1987) 80:491–501.
  • PELHAM WE, GREENSLADE KE, VODDE-HAMILTON M et al.: Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics (1990) 86:226–237.
  • FITZPATRICK PA, KLORMAN R, BRUMAGHM JT et al.: Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder./ Am. Acad. Child. Adol Psychiatry (1992) 31:226–234.
  • KENT JD, BLADER JC, KOPLEWICZ HS et al.: Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics (1995) 96:320–325.
  • STEIN MA, BLONDIS TA, SCHNITZER ER et al.: Methylphenidate dosing: twice daily versus three times daily. Pediatrics (1996) 98:748–756.
  • COMMITTEE ON CHILDREN WITH DISABILITIES AND COMMITTEE ON DRUGS. Medication for children with attentional disorders. Pediatrics (1996) 98:301–304.
  • SWANSON J, KINSBOURNE M, ROBERTS W, ZUCKER K: Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics (1978) 61:21–29.
  • SWANSON J, GUPTA S, LAM k SHOULSON I, LERNER M, MODI N: Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (2003) 60:204–211.
  • SWANSON J, GUPTA S, GUINTA D et al.: Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin. Pharmacol Ther. (1999) 66:295–305.
  • SWANSON JM, GUPTA S, WILLIAMS L, AGLER D, LERNER M, WIGAL S: Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J. Am. Acad. Child. Adolesc. Psychiatry (2002) 41:1306–1314.
  • PELHAM WE, GNAGY EM, BURROWS-MACLEAN L et al.: Once-a-day methylphenidate versus three-times-daily methylphenidate. Pediatrics (2001) 107:1417–1418.
  • HENRY C: Special delivery - alternative methods for delivering drugs improve performance, convenience and patient compliance. Chem. Eng. News (2000) 78 (38) :49–65.
  • WAGNER MW, MARKOWITZ JS, PATRICK KS: Methylphenidate ER lodging in esophagus [letter]. J. Am. Acad. Child. Adolesc. Psychiatry (2001) 40:1244–1245.
  • WOLRAICH ML, GREENHILL LL, PELT-JAM W et al.: Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics (2001) 108(4):883–892.
  • WILENS TE, BIEDERMAN J, LERNER M, and the Concerta Study Group: Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/ hyperactivity disorder. J. Clin. Psychopharm. (2004) 24(1):36–41.
  • COX DJ, MERKEL RL, PENBERTHY JK, KOVATCHEV B, HANKIN CS: Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: A pilot study. J. Am. Aced. Child. Adolesc. Psychiatry (2004) (3):269–275.
  • JAFFE SL: Failed attempt at intranasal abuse of Concerta [letter]. J. Am. Acad. Child. Adolesc. Psychiatry (2002) 41:5.
  • MASSELLO W 3rd, CARPENTER DA: A fatality due to the intranasal abuse of methylphenidate (Ritalin®). J. Forensic Sci. (1999) 44(1):220–221.
  • GARLAND EJ: Intranasal abuse of prescribed methylphenidate. J. Am. Acad. Child. Adolesc. Psych. (1998) 37(0:573–574.
  • STOOPS WW, GLASER PE, RUSH CR: Reinforcing, subject-rated and physiological effects of intranasal methylphenidate in humans: a dose-response analysis. Drug Alcohol Depend. (2003) 71:179–186.
  • VOLKOWN, SWANSON J: Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry (2003) 160(11):1909–1918.
  • KOLLINS SH: Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J. Clin. Psychiatry (2003) 64\(Suppl. 11):14–18.
  • CELLTECH PHARMACEUTICALS, INC: Metadate CD® (methylphenidate HCB package insert. (2001) Rochester, NY.
  • SWANSON JM, WIGAL SB, WIGAL T et al.: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics (2004) 113(3):e206–e216.
  • NOVARTIS PHARMACEUTICALS CORPORATION: Ritalin® LA (methylphenidate HCl) package insert. (2002) East Hanover, NJ.
  • LEE L, KEPPLE J, WANG Y, FREESTONE S, BAKHTIAR R, WANG Y, HOSSAIN M: Bioavailability of modified-release methylphenidate: Influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biop harm. Drug Dispos. (2003) 24(0:233–243.
  • LOPEZ F, SILVA R, PESTREICH L, MUNIZ R: Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatric Drugs (2003) 5(8):545–555.

Websites

  • Concerta (methylphenidate HCI) Extended-Release Tablets. Company: Alza Corporation. Application No.:21–121. Available from http://www.fda.gov/cder/ approval/index. Accessed April 15, 2003.
  • NIH Consensus Development Program. Diagnosis and treatment of attention deficit hyperactivity disorder. NIH Consens. Statement 1998 Nov. 16–18; 16(2):1–37. Available from http://odp.od.nih.gov/ consensus/cons/110/110_statement.htm. Accessed March 25, 2003.
  • FDA Approved Drug Products with Therapeutic Equivalence Ratings. Available from http://www.fda.gov/cder/ob/docs/ preface/ectablec.htm. Accessed March 24, 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.